NRX Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
NRX Pharmaceuticals, Inc. (NRXP) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$300.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$232.00K, a 271.85% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$68.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $913.00K, a 90.97% decline year-over-year.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$210.00K.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $501.00K, a 94.99% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $10.01M.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$531.00K, a 118.05% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $2.94M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$300.00K 10-Q · filed 2026-08-14 | $613.00K derived: sum of 3 quarters · filed 2026-08-14 | $403.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$68.00K 10-Q · filed 2026-05-15 | $845.00K derived: sum of 2 quarters · filed 2026-05-15 | $635.00K derived: sum of 3 quarters · filed 2026-05-15 | $770.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $913.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $703.00K derived: sum of 2 quarters · filed 2026-03-23 | $838.00K derived: sum of 3 quarters · filed 2026-08-14 | $501.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | -$210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$75.00K derived: sum of 2 quarters · filed 2026-08-14 | -$412.00K 10-Q · filed 2025-11-14 | $9.70M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$202.00K 10-Q · filed 2026-08-14 | $9.91M derived: sum of 3 quarters · filed 2026-08-14 | $8.97M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$337.00K 10-Q · filed 2026-05-15 | $9.77M derived: sum of 2 quarters · filed 2026-05-15 | $8.84M derived: sum of 3 quarters · filed 2026-05-15 | $9.72M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $9.18M derived: sum of 2 quarters · filed 2026-03-23 | $10.06M derived: sum of 3 quarters · filed 2026-03-23 | $10.01M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | -$936.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$52.00K derived: sum of 2 quarters · filed 2025-11-14 | -$106.00K 10-Q · filed 2025-11-14 | -$171.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $884.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $830.00K 10-Q · filed 2025-08-18 | $765.00K derived: sum of 3 quarters · filed 2025-08-18 | -$580.00K derived: sum of 4 quarters · filed 2025-08-18 | ||
| 2024-03-31 | -$54.00K 10-Q · filed 2025-05-15 | -$119.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.46M derived: sum of 3 quarters · filed 2025-05-15 | -$890.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$1.41M derived: sum of 2 quarters · filed 2025-03-14 | -$836.00K derived: sum of 3 quarters · filed 2025-03-14 | -$531.00K 10-K · filed 2025-03-14 | ||
| 2023-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$771.00K derived: sum of 2 quarters · filed 2024-11-14 | -$466.00K 10-Q · filed 2024-11-14 | -$515.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $574.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $879.00K 10-Q · filed 2024-08-14 | $830.00K derived: sum of 3 quarters · filed 2024-08-14 | $2.66M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $305.00K 10-Q · filed 2024-05-14 | $256.00K derived: sum of 2 quarters · filed 2024-05-14 | $2.09M derived: sum of 3 quarters · filed 2024-05-14 | $1.61M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.78M derived: sum of 2 quarters · filed 2024-03-29 | $1.30M derived: sum of 3 quarters · filed 2024-03-29 | $2.94M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.35M derived: sum of 2 quarters · filed 2023-11-14 | $2.99M 10-Q · filed 2023-11-14 | $2.69M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.16M 10-Q · filed 2023-08-14 | $851.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.36M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.64M 10-Q · filed 2023-05-15 | $1.33M derived: sum of 2 quarters · filed 2023-05-15 | $1.84M derived: sum of 3 quarters · filed 2023-05-15 | $1.90M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $204.00K derived: sum of 2 quarters · filed 2023-03-31 | $257.00K derived: sum of 3 quarters · filed 2023-03-31 | -$901.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $563.00K derived: sum of 2 quarters · filed 2022-11-14 | -$595.00K 10-Q · filed 2022-11-14 | -$594.44K 10-Q · filed 2021-11-15 | $922.60K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.10M 10-Q · filed 2022-08-15 | -$1.10M 10-Q · filed 2021-08-16 | $412.60K derived: sum of 3 quarters · filed 2022-08-15 | $2.14M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$1.16M 10-Q · filed 2022-05-16 | $359.60K derived: sum of 2 quarters · filed 2022-05-16 | $2.09M derived: sum of 3 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $1.52M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $3.25M derived: sum of 2 quarters · filed 2022-08-12 | $3.24M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.73M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $1.73M 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | -$1.45K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |